Press release
Primary Sclerosing Cholangitis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics
The Primary Sclerosing Cholangitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, FDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Primary Sclerosing Cholangitis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Sclerosing Cholangitis Market.
Some of the key takeaways from the Primary Sclerosing Cholangitis Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Primary Sclerosing Cholangitis treatment therapies with a considerable amount of success over the years.
*
Primary Sclerosing Cholangitis companies working in the treatment market are Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, CymaBay Therapeutics, Ipsen, Genfit, Albireo, and others, are developing therapies for the Primary Sclerosing Cholangitis treatment
*
Emerging Primary Sclerosing Cholangitis therapies in the different phases of clinical trials are- Research programme-antifibrotic therapeutics, GRI-0124, QBT-002, STP707, CS0159, CM 101, Volixibat, PLN-74809 (bexotegrast), HTD1801, Norursodeoxycholic acid, Volixibat, Seladelpar, Elafibranor, A3907, and others are expected to have a significant impact on the Primary Sclerosing Cholangitis market in the coming years.
*
In November 2023, Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech firm dedicated to pioneering treatments for fibro-inflammatory diseases with significant unmet needs, has revealed that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to CM-101 for treating primary sclerosing cholangitis (PSC) in adult patients. PSC is a fibrotic liver ailment associated with risks like liver transplant, cancer, and premature mortality.
*
In September 2023, Pliant Therapeutics, Inc. (Nasdaq: PLRX), has announced encouraging findings from the INTEGRIS-PSC Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The trial successfully achieved its primary and secondary objectives, indicating favorable tolerance of bexotegrast over a 12-week treatment period, with its plasma levels escalating proportionally to dosage. Furthermore, the trial explored efficacy through endpoints such as alterations in liver fibrosis markers (including Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels), liver biochemistry, and magnetic resonance imaging (MRI) of the liver.
*
In March 2023, Pliant Therapeutics, Inc. revealed the initiation of enrollment in a Phase IIa trial of bexotegrast at a dosage of 320 mg administered once daily for a duration ranging from at least 24 weeks to up to 48 weeks. This trial focuses on patients diagnosed with primary sclerosing cholangitis (PSC) following a favorable safety review conducted by an independent Data Safety Monitoring Board (DSMB).
Primary Sclerosing Cholangitis Overview
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation and scarring (fibrosis) of the bile ducts inside and outside the liver. These bile ducts, which carry digestive fluids called bile from the liver to the gallbladder and small intestine, become narrowed, blocked, and eventually destroyed in PSC.
Get a Free Sample PDF Report to know more about Primary Sclerosing Cholangitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-pipeline-insight [https://www.delveinsight.com/report-store/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Primary Sclerosing Cholangitis Drugs Under Different Phases of Clinical Development Include:
*
Research programme: antifibrotic therapeutics Engitix
*
GRI-0124: GRI Bio
*
QBT-002: Qing Bile Therapeutics
*
STP707: Sirnaomics
*
CS0159: Cascade Pharmaceuticals
*
CM 101: Chemomab Therapeutics
*
Volixibat: Mirum Pharmaceuticals
*
PLN-74809 (bexotegrast): Pliant Therapeutics, Inc.
*
HTD1801: HighTide Biopharma
*
Norursodeoxycholic acid: Dr. Falk Pharma
*
Volixibat: Mirum Pharmaceuticals
*
Seladelpar: CymaBay Therapeutics
*
Elafibranor: Ipsen/Genfit
*
A3907: Albireo/IPSEN
Primary Sclerosing Cholangitis Route of Administration
Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravitreal
*
Subretinal
*
Topical
*
Molecule Type
Primary Sclerosing Cholangitis Molecule Type
Primary Sclerosing Cholangitis Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
*
Product Type
Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment
*
Primary Sclerosing Cholangitis Assessment by Product Type
*
Primary Sclerosing Cholangitis By Stage and Product Type
*
Primary Sclerosing Cholangitis Assessment by Route of Administration
*
Primary Sclerosing Cholangitis By Stage and Route of Administration
*
Primary Sclerosing Cholangitis Assessment by Molecule Type
*
Primary Sclerosing Cholangitis by Stage and Molecule Type
DelveInsight's Primary Sclerosing Cholangitis Report covers around 14+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Primary Sclerosing Cholangitis product details are provided in the report. Download the Primary Sclerosing Cholangitis pipeline report to learn more about the emerging Primary Sclerosing Cholangitis therapies [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Primary Sclerosing Cholangitis Therapeutics Market include:
Key companies developing therapies for Primary Sclerosing Cholangitis are - HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., Chemomab Therapeutics, CymaBay Therapeutics, Genfit, Albireo, IPSEN, and others.
Primary Sclerosing Cholangitis Pipeline Analysis:
The Primary Sclerosing Cholangitis pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Primary Sclerosing Cholangitis with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.
*
Primary Sclerosing Cholangitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Primary Sclerosing Cholangitis drugs and therapies [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Primary Sclerosing Cholangitis Pipeline Market Drivers
*
Increasing prevalence of diseases associated with PSC such as liver cancer and inflammatory bowel disease, A rising number of research studies on PSC are some of the important factors that are fueling the Primary Sclerosing Cholangitis Market.
Primary Sclerosing Cholangitis Pipeline Market Barriers
*
However, withdrawal of molecules from late clinical stages, lack of skilled professionals or trained expertise and other factors are creating obstacles in the Primary Sclerosing Cholangitis Market growth.
Scope of Primary Sclerosing Cholangitis Pipeline Drug Insight
*
Coverage: Global
*
Key Primary Sclerosing Cholangitis Companies: Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, CymaBay Therapeutics, Ipsen, Genfit, Albireo, and others
*
Key Primary Sclerosing Cholangitis Therapies: Research programme-antifibrotic therapeutics, GRI-0124, QBT-002, STP707, CS0159, CM 101, Volixibat, PLN-74809 (bexotegrast), HTD1801, Norursodeoxycholic acid, Volixibat, Seladelpar, Elafibranor, A3907, and others
*
Primary Sclerosing Cholangitis Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and Primary Sclerosing Cholangitis emerging therapies
*
Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis market drivers and Primary Sclerosing Cholangitis market barriers
Request for Sample PDF Report for Primary Sclerosing Cholangitis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Primary Sclerosing Cholangitis Report Introduction
2. Primary Sclerosing Cholangitis Executive Summary
3. Primary Sclerosing Cholangitis Overview
4. Primary Sclerosing Cholangitis- Analytical Perspective In-depth Commercial Assessment
5. Primary Sclerosing Cholangitis Pipeline Therapeutics
6. Primary Sclerosing Cholangitis Late Stage Products (Phase II/III)
7. Primary Sclerosing Cholangitis Mid Stage Products (Phase II)
8. Primary Sclerosing Cholangitis Early Stage Products (Phase I)
9. Primary Sclerosing Cholangitis Preclinical Stage Products
10. Primary Sclerosing Cholangitis Therapeutics Assessment
11. Primary Sclerosing Cholangitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Primary Sclerosing Cholangitis Key Companies
14. Primary Sclerosing Cholangitis Key Products
15. Primary Sclerosing Cholangitis Unmet Needs
16 . Primary Sclerosing Cholangitis Market Drivers and Barriers
17. Primary Sclerosing Cholangitis Future Perspectives and Conclusion
18. Primary Sclerosing Cholangitis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-sclerosing-cholangitis-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-engitix-gri-bio-qing-bile-therapeutics-sirnaomics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Sclerosing Cholangitis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics here
News-ID: 3476657 • Views: …
More Releases from ABNewswire
Rhinitis Pipeline 2025: Innovative Clinical Breakthroughs Led by 35+ Global Lead …
DelveInsight's, "Rhinitis - Pipeline Insight, 2025," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Rhinitis companies are Abdi Ibrahim Pharmaceuticals, Lyra Therapeutics, Inmunotek, Iltoo Pharma, Advagene…
ANCA Vasculitis Pipeline 2025: Pioneering Clinical Progress Driven by 12+ Global …
DelveInsight's, "ANCA Vasculitis - Pipeline Insight, 2025," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in ANCA Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The ANCA vasculitis (anti-neutrophil cytoplasmic antibody-associated vasculitis) market, a rare…
Autoimmune uveitis Market: Epidemiology, Therapies, Companies, DelveInsight | Ta …
The Autoimmune Uveitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Autoimmune Uveitis market size from 2020 to 2034. The Autoimmune Uveitis market report also covers current Autoimmune Uveitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Autoimmune Uveitis market.
Therapies for autoimmune uveitis, including YUTIQ, HUMIRA (Adalimumab), TRS01,…
Cutaneous lupus erythematosus Market: Epidemiology, Therapies, Companies, DelveI …
Cutaneous Lupus Erythematosus Treatment Market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Cutaneous Lupus Erythematosus market size from 2020 to 2034. The report also covers current Cutaneous Lupus Erythematosus treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Therapies for cutaneous lupus erythematosus, including Litifilimab, Daxdilimab, and others, are anticipated to drive…
More Releases for Primary
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market
Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics
The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031.
Primary Biliary Cholangitis (PBC), formerly known as…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
